ClinicalTrials.gg
CompletedNCT06849791Updated Jun 4, 2026

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

A Phase 1 interventional study of ABBV-932 and ABBV-932 in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    ABBV-932: Arm A

    Participants will receive a single dose of ABBV-932 Arm A on day 1 under fasting conditions.

    Drug: ABBV-932

  • Experimental
    ABBV-932: Arm B

    Participants will receive a single dose of ABBV-932 Arm B on day 1 under fasting conditions.

    Drug: ABBV-932

  • Experimental
    ABBV-932: Arm C

    Participants will receive a single dose of ABBV-932 Arm C on day 1 under fasting conditions.

    Drug: ABBV-932

  • Experimental
    ABBV-932: Arm D

    Participants will receive a single dose of ABBV-932 Arm D on day 1 with a high-fat meal.

    Drug: ABBV-932

  • Experimental
    ABBV-932: Arm E

    Participants will receive a single dose of ABBV-932 Arm E on day 1 with a high-fat meal.

    Drug: ABBV-932

  • Experimental
    ABBV-932: Arm F

    Participants will receive a single dose of ABBV-932 Arm F on day 1 under fasting conditions.

    Drug: ABBV-932

  • Experimental
    ABBV-932: Arm G

    Participants will receive a single dose of ABBV-932 Arm G on day 1 with a high-fat meal.

    Drug: ABBV-932

  • Experimental
    ABBV-932: Arm H

    Participants will receive a single dose of ABBV-932 Arm H on day 1 under fasting conditions.

    Drug: ABBV-932

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of ABBV-932

    Cmax of ABBV-932

    Time frame: Up to approximately 6 days

  2. Time to Cmax (Tmax) of ABBV-932

    Tmax of ABBV-932

    Time frame: Up to approximately 6 days

  3. Terminal Phase Elimination Rate Constant (Beta) of ABBV-932

    Terminal phase elimination rate constant (beta) of ABBV-932

    Time frame: Up to approximately 6 days

  4. Terminal Phase Elimination Half-Life (t1/2) of ABBV-932

    Terminal phase elimination half-life of ABBV-932

    Time frame: Up to approximately 6 days

  5. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932

    AUCt of ABBV-932

    Time frame: Up to approximately 6 days

  6. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932

    AUCinf of ABBV-932

    Time frame: Up to approximately 6 days

  7. Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 180 days

07

Study locations

1 site
  • Acpru /Id# 266649
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in May 2026, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Feb 27, 2025
StartActual
Feb 26, 2025
Primary completionActual
May 8, 2026
CompletionActual
May 8, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06849791
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
Feb 26, 2025
Primary completion
May 8, 2026
Completion
May 8, 2026
Last update
Jun 4, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-932

Start the discussion